The Silent Dropout: What Happens After Patients Call? 1K+ Survey Responses Tell the Story
Why patients who seem "engaged" disappear... and what site behaviors may be driving them away
Newsletter
When Engineering Meets Research Legacy: Inside the AtaiBeckley Merger
The AtaiBeckley merger reflects a bet that shorter treatment durations will improve patient access and payer acceptance.
From Telecom to THC: How an Engineer Tackled Alzheimer's Agitation
An engineer's path from NASDAQ IPO to hemp-derived THC trials reveals the operational realities many clin ops teams don't discuss.
The Clinical Execution Playbook Behind Schizophrenia's First New Mechanism
How Karuna's former CMO turned disciplined trial methodology into a $14 billion BMS acquisition
Your Sites Are Losing Patients on Phone Screens (And You'd Never Know)
Why the gap between 'interested patient' and 'scheduled screening' is costing you enrollment
The Alzheimer's Hypothesis Big Pharma Missed
Why a former Genentech director bet on cortisol over amyloid, and what pilot data showing 5x better efficacy could mean for patients
Human or AI Voice Agents? Choosing the Right Pre-Screening Model for Your Trial
What happens when a qualified patient is ready to engage... and nobody's available to respond?